Open AccessWell tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus–coinfected patients treated by all-oral direct-acting antivirals
Author(s) -
Pin Shuo Su,
Chien Wei Su,
Sih Hsien Wu,
Tien Hsin Wei,
ChiJen Chu,
Chih-Chieh Lin,
Shou Dong Lee,
Yuan Jen Wang,
Fa Yauh Lee,
Yi Hsiang Huang,
Ming Hou
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000528
Subject(s) - ombitasvir , paritaprevir , medicine , daclatasvir , dasabuvir , sofosbuvir , coinfection , tolerability , ledipasvir , ritonavir , simeprevir , hepatitis c , gastroenterology , hepatitis c virus , pegylated interferon , viral load , ribavirin , virology , adverse effect , virus , antiretroviral therapy
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection is common because the two pathogens share their transmission route. Studies have suggested that coinfection is associated with accelerated hepatic fibrosis, increased hepatic decompensation, and hepatocellular carcinoma development. Historically, the sustained virological response (SVR) rates for patients undergoing pegylated interferon (PEG-IFN)-based therapy are poor owing to advanced liver disease, immune dysfunction, and poor medical adherence. This study aimed to investigate the efficacy and safety of oral direct-acting antivirals (DAAs) in HCV-HIV-coinfected patients.